{"brief_title": "Effects of Teriparatide in Postmenopausal Women With Osteoporosis", "brief_summary": "Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.", "condition": ["Postmenopausal Osteoporosis"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["teriparatide", "aldrenodate", "raloxifene"], "criteria": "Inclusion Criteria: - Postmenopausal women aged at least 50 years - A previous clinical diagnosis of osteoporosis - At high risk for fracture - Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na Exclusion Criteria: - History of metabolic bone disease other than osteoporosis - History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma", "gender": "Female", "minimum_age": "50 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Osteoporosis", "Osteoporosis, Postmenopausal", "Teriparatide", "Raloxifene Hydrochloride"], "id": "NCT00079924"}